Halozyme Therapeutics, Inc.
HALO · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $1.40B | $1.02B | +37.6% |
| Operating income | $469M | $551M | −15.0% |
| Net income | $317M | $444M | −28.6% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $493M | $354M | +39.1% |
| Operating income | $295M | $218M | +35.4% |
| Net income | $247M | $175M | +41.0% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Halozyme's revenue in FY2025?
- $1.40B in FY2025 (Fiscal year ended Dec 31, 2025), +37.6% vs $1.02B a year earlier, per its 10-K filed Feb 2026.
- Was Halozyme profitable in FY2025?
- Yes: net income was $317M and operating income $469M in FY2025.
- What was Halozyme's revenue in Q3 2026?
- $493M (+39.1% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.